Researchers at EPFL have developed BindCraft, a cutting-edge AI pipeline that achieves unprecedented success rates (10–100%) in functional protein binder design with strong affinity, bypassing traditional resource-intensive screening methods. The model’s 'one-shot' approach generates multiple high-affinity binders rapidly for diverse targets, including allergens and CRISPR complexes. BindCraft is openly available under the MIT license, potentially transforming protein engineering for therapeutic and biotechnological applications.